Back to All

Issue of Share Options/PDMR Shareholdings

6 April, 2021

Diaceutics PLC

(“Diaceutics” or the “Company”)

Issue of Share Options/PDMR Shareholdings

Diaceutics PLC (AIM: DXRX), the diagnostic commercialisation company, announces the issue of share options over ordinary shares of £0.002 each in the Company (“Share Options”) to certain Directors, members of the Company’s senior management team and other key staff, pursuant to the Company’s Employee Share Option Plan (“ESOP”). These awards are made in accordance with the Company’s long term incentive plan.

Share Options were granted as follows:

Name

Number of Share Options granted

Total no. of ordinary shares under option post grant

% of existing issued share capital

Effective Grant date

Peter Keeling, CEO

73,542

253,542

0.30%

1 April 2021

Philip White, CFO

64,154

244,154

0.29%

1 April 2021

Ryan Keeling, CIO

64,154

244,154

0.29%

1 April 2021

Damian Thornton, COO and PDMR

64,062

            166,766

0.20%

1 April 2021

Jordan Clark, CCO and PDMR

46,003

122,117

0.15%

1 April 2021

Susanne Munksted, PDMR

45,475

116,147

0.14%

1 April 2021

Other employees (36 persons)

534,581

869,811

1.03%

   1 April 2021

The Share Options vest on a sliding scale up to 100%, after three years from the date of grant (the “Performance Period”), subject to the satisfaction of certain performance criteria. The performance criteria is based upon the growth in Total Shareholder Return, measured using the average mid-market closing share price in the month immediately before the end of the Performance Period, plus any dividends declared and paid during the Performance Period. The growth in TSR will be measured against a base share price of 102.67p, being the average mid-market closing share price in the three days prior to 1 April 2021, when the options were issued. The exercise price of the Share Options is £0.002 per share which equates to the nominal value of the shares.

Following this grant, the total number of share options outstanding in the Company is 2,016,687, representing approximately 2.4% of its current issued share capital of 84,063,923.

Enquiries:

Diaceutics PLC

www.diaceutics.com

Peter Keeling, Chief Executive Officer

via Walbrook PR

Philip White, Chief Financial Officer


 


Cenkos Securities plc (Nominated adviser and broker)

+44 (0)207 397 8900

Callum Davidson / Giles Balleny


Michael Johnson (Sales)


 


Walbrook PR

Tel: +44 (0)20 7933 8780 or [email protected]

Anna Dunphy

Mob: +44 (0)7876 741 001

Paul McManus

Mob: +44 (0)7980 541 893





About Diaceutics

At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX – our Proprietary Diagnostic Network solution for the development and commercialisation of precision medicine diagnostics. Diaceutics has worked on every precision medicine brought to market and provides solutions to 36 of the world’s leading pharmaceutical companies. DXRX – the Diagnostic Network ® provides unrivalled access to deep analysis and insights from the world’s largest repository of diagnostic testing data on one secure platform. www.diaceutics.com

About DXRX – The Diagnostic Network®

DXRX is Diaceutics’ proprietary diagnostic network for precision medicine. DXRX is an end-to-end solution for the development and commercialisation of Precision Medicine diagnostics. The platform enables a vibrant marketplace where all stakeholders in Precision Medicine come to find trusted partners and collaborations in a secure, standardised way. DXRX provides access to a pipeline of global diagnostic testing data on one secure platform.

About Diaceutics

At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX - the world’s first Network solution for the development and commercialization of precision medicine diagnostics. 

Diaceutics has worked on every precision medicine brought to market and provides services to 36 of the world’s leading pharmaceutical companies. We have built the world’s largest repository of diagnostic testing data with a growing network of 2500 labs in 51 countries.

Diaceutics PLC


Philip White
Chief Financial Officer
+44 (0) 7801 611 921


Nominated adviser and broker

Stifel Nicolaus Europe Limited
150 Cheapside
London
EC2V 6ET.

Public Relations & Investor Relations advisers

Alma PR
71-73 Carter Lane
London
EC4V 5EQ.

Tel: +44 (0)20 3405 0205 or [email protected]


 
Caroline Forde
Robyn Fisher
 
Kieran Breheny